C4 Therapeutics, Inc. (CCCC) is a leading biopharmaceutical company that is revolutionizing the treatment of cancer and other life-threatening diseases through an innovative, targeted protein degradation (TPD) technology. Incorporated in 2015 and based in the biotech hub of Cambridge, Massachusetts, the company is publicly traded under the ticker symbol CCCC on the NASDAQ stock exchange.
C4 Therapeutics is recognized for its advanced research and development of small molecule drugs that leverage the body's natural protein disposal system. Utilizing their proprietary DEGRONIMID™ platform, they develop treatments that selectively tag disease-causing proteins for degradation, thereby disrupting their activities. This unique technology provides numerous advantages over traditional therapies, including increased efficacy, higher specificity, and reduced cytotoxic effects.
C4 Therapeutics is pioneering this transformative approach to therapy across several therapeutic areas. The company’s robust drug discovery engine and broad intellectual property portfolio have led to a diverse pipeline of product candidates addressing multiple indications, primarily in oncology such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and prostate cancer. These therapies are designed to overcome limitations of current treatment options and offer hope to patients who have run out of options.
The company's collaborative approach is another hallmark of its strategy. They have established several strategic partnerships with leading pharmaceutical companies, including Roche and Calico, that accelerate development and enable C4 Therapeutics to pursue a range of disease targets.
C4 Therapeutics follows a relentless commitment to scientific excellence, patient safety and ethical business conduct. The company's team consists of world-class scientists, clinicians, and professionals committed to making a transformative impact on patient care. At C4 Therapeutics, unmet medical needs drive innovation, and the ultimate goal is to improve and extend the lives of patients around the globe.
Despite the extremely complex and high-risk nature of drug development, C4 Therapeutics has so far exhibited promising potential. The company has already attracted significant interest from investors, buoyed by the desire for innovative and effective treatments for cancer and other serious diseases. The company's growth and development are anticipated to continue in the years to come as they work towards bringing their groundbreaking therapies from bench to bedside.
In conclusion, C4 Therapeutics, Inc. (CCCC) is at the forefront of the biopharmaceutical industry as they champion a revolutionary technology poised to improve the lives of patients burdened with cancer and other life-threatening diseases. They are an exemplar of innovative thinking, strategic collaboration, and a relentless pursuit of life-changing therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
C4 Therapeutics (CCCC) saw its short interest increase to 38.09% of its float as of October 30th, up 9.03% from October 15th, totaling 46,580,600 shares. This indicates it would take short sellers approximately 15.14 days to cover their positions at current trading volumes. Additionally, the article highlights significant institutional investor activity, with 94 investors adding to their positions and 62 decreasing them in recent quarters.
C4 Therapeutics (CCCC) reported a narrower-than-expected Q3 loss of $0.16 per share, beating the Zacks Consensus Estimate of -$0.20, and marking its fourth consecutive quarter of surpassing EPS estimates. However, the company missed revenue expectations, posting $8.47 million against an estimated $8.93 million. Despite the revenue miss, C4 Therapeutics stock has significantly outperformed the S&P 500 year-to-date, gaining 63.4% compared to the index's 12.3%.
C4 Therapeutics (C4T) reported its third-quarter 2026 financial results, highlighting progress in its cemsidomide clinical trials for multiple myeloma. The company expects to complete enrollment for its Phase 2 MOMENTUM trial in Q1 2027 and present initial ORR data in H2 2027. C4T also advanced its Phase 1b trial of cemsidomide with elranatamab and anticipates new data from all evaluated cohorts in mid-2027, projecting its current cash will fund operations until the end of 2028.
C4 Therapeutics, Inc. (C4T) announced that its management will participate in two upcoming investor conferences in November. These include the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, and the Jefferies Global Healthcare Conference in London on November 17, 2026. Live webcasts of both events will be available on the company's website.
C4 Therapeutics (C4T) has expanded its discovery platform by integrating a novel DNA-encoded library (DEL) into its TORPEDO® platform, enabling a target-centric approach to identify new molecular glue degraders. This new capability, which leverages C4T's cereblon-binding ligands, has already shown promising results in identifying hits against high-value targets within four months. C4T plans to utilize this enhanced platform to advance its internal pipeline focused on inflammation, neuroinflammation, and neurodegenerative diseases, and to pursue collaborations.
C4 Therapeutics (C4T) has expanded its discovery platform with a novel DNA-encoded library (DEL) that leverages its cereblon-binding ligands and screening capabilities to rapidly identify molecular glue degraders. This target-first approach, integrated into its TORPEDO® platform, has already delivered hits against high-value targets within four months. C4T plans to utilize this technology for its internal pipeline and potential partnerships, focusing on targets in inflammation and neurodegenerative diseases.